Coating a single-layer appositional jejunal anastomosis with SCMC or HA solutions does not adversely affect anastomotic healing. Application of 0.4% HA solution to the serosal surface of the jejunum significantly decreases the incidence of experimentally induced intra-abdominal adhesion formation in horses.

In colic- or colitis-affected horses, factors associated with renal insufficiency included gastric reflux, abnormal rectal examination findings, or hypochloremia initially; prognosis for horses in which azotemia resolves within 72 hours of treatment appears to be better than for horses with persistent azotemia.

Summary Haemothorax is an uncommon, although clinically important, condition in horses of all ages and has a wide range of aetiologies. Clinical signs can include tachypnoea, dyspnoea, tachycardia, absence of bronchovesicular sounds, haemoptysis, colic and death. The most common aetiologies are associated with trauma, neoplasia, coagulation disorders, iatrogenic causes and vessel rupture. Diagnosis is made if there is evidence of thoracic fluid on ultrasonography and confirmation of haemorrhage by thoracocentesis. The goals of treatment are to address the primary cause and provide supportive care. Prognosis depends on aetiology, severity of active bleeding and volume of blood loss.

Background Prognosis associated with lymphoma in horses is poorly characterized, and treatment is often palliative. Long‐term outcome after chemotherapy for horses with lymphoma is not well documented. Objective To report long‐term outcome of horses with lymphoma treated with chemotherapy. Animals Fifteen equids. Methods Retrospective case series. Medical record search and call for cases on the ACVIM listserv for horses treated with chemotherapy for lymphoma. Results Fifteen cases with adequate data were identified. Complete remission was achieved in 5 horses (33.3%), partial response was achieved in 9 equids (60%), and stable disease was achieved in 1 horse. Overall response rate was 93.3% (14/15). Overall median survival time was 8 months (range, 1‐46 months). Nine horses experienced a total of 14 adverse effects attributable to chemotherapy. Adverse effects were graded according to the Veterinary Cooperative Oncology Group common terminology criteria for adverse events grading system (grade 1 alopecia, n = 2; grade 1 neutropenia, n = 2; grade 1 lymphopenia, n = 3; grade 1 lethargy, n = 1; grade 2 neurotoxicity, n = 1; grade 2 colic, n = 1; grade 1 hypersensitivity, n = 1; grade 2 hypersensitivity, n = 2; grade 5 hypersensitivity, n = 1). Higher grade adverse effects most commonly were associated with doxorubicin administration (n = 4), including 1 horse that died 18 hours post‐administration. Conclusions and Clinical Importance Chemotherapy can be used successfully for treatment of horses with lymphoma. Adverse effects, most commonly mild, occurred in approximately two‐thirds of treated horses.